The positive effect of the pandemic: Virtualization and Advanced Analytics for the next-generation clinical trials
Sponsored by: Exom Group Srl.
- Covid 19
Date: 23 November
Days to go: 28
Time: 2PM London / 3pm CET
How digital technologies modernize clinical trials and how patients, investigators and sponsors will benefit from this change.
Digital technologies have been used in clinical studies for years. So far, however, they have been used very hesitantly by sponsors, study centers and CROs. Authorities have also been very hesitant to approve their use.
The Covid-19 pandemic, however, has changed this attitude. Innovative Digital technologies, such as telemedicine or remote informed consent and site monitoring, rapidly found their way into clinical trials, and regulatory authorities, sponsors, investigators and patients are ready to break new grounds.
The path Exom has taken with its customers since its founding, namely to conduct clinical trials using innovative technologies and advanced analytics, has proven to be the right one.
In this webinar we will show, from the perspective of a sponsor and a CRO, the following points:
• How studies can be conducted virtually
• How advanced analytics and machine learning can be used in different areas of study execution
• How study stakeholders can benefit from these innovations
Register now to save your space!
Head of Clinical and RWE Outsourcing Management, Chiesi Farmaceutici S.p.A.
Clinical Operations Director
Marco Villa is a professional in clinical research with an experience of over 15-years, working both in pharmaceutical companies and CRO business. After the university degree in pharmaceutical chemistry and technologies, he started a career as CRA in 2004. Three years later Marco became a project manager, a role that he covered for nine years, working on local and international studies, both interventional and non-interventional, in several therapeutic areas, including oncology, cardiology, respiratory and infectious diseases. He managed the largest trial ever done in acute pulmonary embolism.
His primary duty at Exom is to support the company to drive the innovation of clinical research through a risk-based and data-driven management of clinical studies, utilizing the most innovative technologies and advanced analytics.
MSc – Chief Development Officer at Exom Group
Holding a Master of Science in Clinical Research from the Danube University Krems and a diploma in Business Administration and Computational Sciences from the Academy of Public and Business Administration in Munich Patrick is bringing more than 12 years of experience in Business Development in the CRO business. During his career, he gained a solid understanding of all aspects of clinical trials and deep knowledge in Business Development. He held several leading positions in the area of Business Development in mid-size CROs.
Key Learning Objectives
- How studies can be conducted virtually
- How advanced analytics and machine learning can be used in different areas of study execution
- How study stakeholders can benefit from these innovations
- VP (Global) Clinical Operations
- Heads of (Global) Clinical Operations
- VP Research & Development
- Heads of Research & Development
- VP of Drug Development
- Heads of Drug Development
- Chief Medical Officers
- Project Managers
- VPs of Procurement
- Heads of Procurement